Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Benefits of My MI

With a free MI account, you can follow specific scholars or subjects, search MI's research archives and past articles, and receive customized news and updates from the Institute. Also, you will be able to manage invitations and registration for MI events, as well as your annual membership renewals. Create your account today to begin exploring MI.

The President’s Precision Medicine Initiative has the potential to be his most significant health care legacy, helping to develop tailored health solutions to millions of Americans.

But much of it will depend on the policies of his successor: and both Secretary Clinton and Donald Trump have called for price controls on new medicines. If we don’t encourage companies to make the large, long-term investments needed to develop precision medicines, sharing data and building databases won’t be enough to deliver new cures.

______________________

Paul Howard is a senior fellow and director of health policy at the Manhattan Institute